Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection

Bibliography

• United Nations Programme on HIV/AIDS (UNAIDS). AIDS epidemic update 2006. December 2006. Available from: http://www.unaids.org/epi/2005 [Accessed 22 July 2007]
   Google Scholar
• Minino AM, Smith L. Deaths: preliminary data for 2000. Natl Vit Stat Rep 2001;49:1-40
   Google Scholar
• Little SJ, Holte S, Routy JP, et al. Antiretroviral drug resistance among patients recently infected with HIV. N Engl J Med 2002;347(6):385-94
   PubMed Web of Science ®Google Scholar
• Braithwaite RS, Justice AC, Change CC, et al. Estimating the proportion of patients infected with HIV who will die of comorbid diseases. Am J Med 2005;118:890-8
   PubMed Web of Science ®Google Scholar
• Hazuda DJ, Felock P, Winner M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000;287(5453):646-50
   PubMed Web of Science ®Google Scholar
• Merck & Company – Research and Development News: Merck Announces Interim Results from Phase II Study of MK-0518, an Investigational Oral HIV Integrase Inhibitor (press release). Available from: http://www.merck.com/newsroom/press_releases/research_and_development/2006_0209.html [Accessed 26 March 2007]
   Google Scholar
• Markowitz M, Morales-Ramirez JO, Nguyen BY. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel HIV-1 integrase inhibitor, dosed as monotherapy for 10 days in treatment-naive HIV-1 infected individuals. J Acquir Immune Defic Syndr 2006;43(5):509-15
   PubMed Web of Science ®Google Scholar
• Kassahun K, McIntosh I, Hreniuk D, et al. Absorption and excretion of the MK-0518, a potent HIV-1 integrase inhibitor, in healthy male volunteers. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 September 27 – 30; San Francisco, CA; A-0372
   Google Scholar
• Markowitz M, Nguyen BY, Gotuzzo F, et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, as part of combination ART in treatment-naïve HIV-1 infected patients. 16th International AIDS Conference; 2006 August 13 – 18; Toronto, Canada; Ab THL0214
   Google Scholar
• Markowitz M, Nguyen B-Y, Gotuzzo F, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study week data. J Acquir Immune Defic Syndr. Epub 2007
   Google Scholar
• Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a Phase II randomized controlled trial. Lancet 2007;369:1261-9
   PubMed Web of Science ®Google Scholar
• Cooper D, Gatell J, Rockstoh J, et al. Results of BENCHMRK-1, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th Conference on Retroviruses and Opportunistic Infections; 2007 February 25 – 28; Los Angeles, California. 2007:1 [Abstract 105aLB]
   Google Scholar
• Steigbigel R, Kumar P, Eron J, et al. Results of BENCHMRK-2, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th Conference on Retroviruses and Opportunistic Infection; 2007 February 25 – 28; Los Angeles, California. 2007:1 [Abstract 105bLB]
   Google Scholar
• McColl DJ, Fransen S, Gupta S, et al. Resistance and cross-resistance to first-generation integrase inhibitors: insights from a Phase II study of elvitegravir (GS-9137). Program and abstracts of the 16th International HIV Drug Resistance Workshop; 2007 June 12 – 16; Barbados, West Indies; [Abstract 9]
   Google Scholar
• Teppler H, Azrolan N, Chen J, et al. differential effects of MK-0518 and efavirenz on serum lipids and lipoproteins in antiretroviral therapy (ARV)-naïve patients (24 Week Results). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 September 27 – 30; San Francisco, CA; Ab H0256a
   Google Scholar
• Iwamoto M, Wenning LA, Petry AA, et al. Minimal effect of ritonavir (RTV) and efavirenz (EFV) on the pharmacokinetics (PK) of MK-0518. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 September 27 – 30; San Francisco, CA; A-0373
   Google Scholar
• Wenning LA, Hanley W, Stone J, et al. Effect of tipranavir + ritonavir (TPV + RTV) on pharmacokinetics of MK-0518. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 September 27 – 30; San Francisco, CA; A-0374
   Google Scholar
• Wenning LA, Friedman E, Kost JT, et al. Lack of significant drug interaction between MK-0518 and Tenofovir disoproxil fumarate (TDF) 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 September 27 – 30; San Francisco, CA; A-0375
   Google Scholar
• Murray JM, Emery S, Kelleher A, et al. The integrase inhibitor raltegravir alters viral decay kinetics of HIV, significantly reducing the second phase and challenging current hypothesis of viral replication. 4th International AIDS Society Conference; 2007 July 22 – 25; Sydney, Australia; (Abstract TUAB103)
   Google Scholar
• Haubrich RH, Riddler S, Ribaudo H, et al. Initial viral decay to assess the relative antiretroviral potency of PI-, NNRTI-, and NRTI-sparing regimens for first line therapy of HIV-1 infection: ACTG 5160s (sub-study of A5142). 14th Conference on Retroviruses and Opportunistic Infections; 2007 February 25 – 28; Los Angeles, California; Abstract 137
   Google Scholar